Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 1, 1997, Pages 33-37

  Ossei Gerning, Nicholas ^a,b,c   Mansfield, Michael W ^a   Stickland, Max H ^a   Wilson, Ian J ^b   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

4G 5G genotype; coronary atheroma; myocardial infarction; plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; THROMBOGENESIS;

EID: 0031028790     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.1.33     Document Type: Article

References (26)

1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-387.
2. ECAT Angina Pcctoris Study Group. ECAT angina pectoris study: base-line associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
3. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
4. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk for recurrent myocardial infarction. Lancet. 1987;2:3-9.
5. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-l in HepG2 cells. J Biol Chem. 1993:268:10739-10745.
6. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activotor inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
7. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44:37-42.
8. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837-841.
9. Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes and in patients with diabetic retinopathy. Thromb Haemost. 1994;71:731-736.
10. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost. 1995;74: 1032-1034.
11. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol. 1986;15:355-370.
12. Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ. 1985:291:573-574.
13. de Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang MT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980:303:897-902.
14. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310:1137-1140.
15. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
16. Kruithof E. Plasminogen activator inhibitors: a review. Enzyme. 1988;40:113-121.
17. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Allan C. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metab. 1987;13:331-336.
18. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost. 1989;61:370-373.
19. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
20. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990:227:273-278.
21. Landin K, Tengbom L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost. 1991;65:130-133.
22. Potter van Loon BJ, Kluft K, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949.
23. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
24. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndromes. Diabetologia. In press.
25. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol. 1986;7:479-483.
26. Egashira K, Tetsuzi I, Yoshitaka H, Akira Y, Yoshitoshi U, Akira T. Evidence of impaired endothelium dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993:328:1659-1664.